Panzem Gets Orphan Drug Status for Treatment of Brain Tumor

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 8
Volume 15
Issue 8

EntreMed, Inc.'s lead drug candidate Panzem (2-methoxyestradiol or 2ME2) has received orphan drug status from the FDA for the treatment of glioblastoma multiforme. In vitro studies in glioma cell lines demonstrated Panzem's antiproliferative activity, and in vivo studies in a preclinical model of glioblastoma showed its antitumor activity, EntreMed said in a press release. Panzem is currently being investigated in a phase II trial in patients with glioblastoma multiforme at the Brain Tumor Center at Duke University Medical Center. The agent previously received orphan drug designation for the treatment of multiple myeloma and ovarian cancer.

ROCKVILLE, Maryland—EntreMed, Inc.'s lead drug candidate Panzem (2-methoxyestradiol or 2ME2) has received orphan drug status from the FDA for the treatment of glioblastoma multiforme. In vitro studies in glioma cell lines demonstrated Panzem's antiproliferative activity, and in vivo studies in a preclinical model of glioblastoma showed its antitumor activity, EntreMed said in a press release. Panzem is currently being investigated in a phase II trial in patients with glioblastoma multiforme at the Brain Tumor Center at Duke University Medical Center. The agent previously received orphan drug designation for the treatment of multiple myeloma and ovarian cancer.

Articles in this issue
Younger Age at Brain Tumor Diagnosis Portends Poor Emotional Outcome
Higher Responses in Metastatic Colon Ca When Cetuximab Added to Chemo
Triple Targeted Therapy Is Tested in Pts With Solid Tumors
FDA Approves Three-Drug Combination Tablet for HIV-1
Side Effects Persist 16 Years After Prostate Ca Brachytherapy
No Significant QOL Differences for Raloxifene and Tamoxifen
Amrubicin Appears Promising in Small-Cell Lung Cancer
R-MP Active in Older Pts With Newly Diagnosed Myeloma
Sunitinib and Sorafenib Active in Phase II Advanced NSCLC Trials
Takeda Signs Agreement With Galaxy Biotech for HuL2G7
Experimental Regimens Fail to Boost Pancreatic Survival
Adding Bortezomib Ups Dual Transplant Results in Myeloma
Demand Spurs Efforts to Improve Recruitment, Retention
Why Has Mortality Related to Pancreatectomy Declined?
Phase III Trial Finds XP as Efficacious as EP as First-Line Therapy for Metastatic Breast Cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Related Content
The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Roman Fabbricatore
July 2nd 2025
Article

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

The safety profile of iopofosine I 131 in the phase 1b CLOVER-2 trial appears consistent with prior reports of the agent.

Iopofosine I 131 Shows Preliminary Survival Benefit in Pediatric R/R Glioma

Russ Conroy
June 11th 2025
Article

The safety profile of iopofosine I 131 in the phase 1b CLOVER-2 trial appears consistent with prior reports of the agent.

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Conducting Early Phase Trials of Promising Treatments in Neuro-Oncology

Shwetal Mehta, PhD
January 27th 2025
Podcast

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Data from the ROSELLA trial may support relacorilant plus nab-paclitaxel as a new standard in this ovarian cancer population.

Relacorilant and Nab-Paclitaxel Significantly Extend PFS in Ovarian Cancer

Gina Mauro
June 2nd 2025
Article

Data from the ROSELLA trial may support relacorilant plus nab-paclitaxel as a new standard in this ovarian cancer population.

Dostarlimab/Chemo, Maintenance Niraparib Show Modest Improvements in Ovarian Cancer

Dostarlimab/Chemo, Maintenance Niraparib Show Modest Improvements in Ovarian Cancer

Tim Cortese
June 2nd 2025
Article

The median PFS with dostarlimab plus niraparib was 20.6 months vs 19.2 months with niraparib alone in patients with treatment-naive advanced ovarian cancer.